Ipratropium/Salbutamol Orion

Salbutamol, the active ingredient in Ipratropium/Salbutamol Orion, is a β2‑adrenergic agonist presented as a combined oral formulation for oral use. It is used to relax airway smooth muscle and improve breathing in patients with obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD).

GNH USA supplies Ipratropium/Salbutamol Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium/Salbutamol is a bronchodilator indicated for conditions involving reversible airway obstruction.

- Asthma: provides rapid relief of bronchospasm and improves airflow during acute episodes. - Chronic obstructive pulmonary disease (COPD): helps reduce airway resistance and ease breathing in stable disease. - Acute bronchospasm: used to quickly open airways during sudden worsening of respiratory symptoms.

Adverse reactions may occur with any bronchodilator therapy.

Common Side Effects: - Tremor: mild shaking of hands or limbs. - Headache: transient headache episodes. - Dry mouth: reduced salivation causing discomfort. - Palpitations: sensation of rapid or irregular heartbeat. - Nausea: mild gastrointestinal upset. - Cough: irritation of the airway.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty. - Angioedema: swelling of lips, tongue or throat. - Severe tachycardia: markedly increased heart rate. - Hypokalemia: low blood potassium levels. - Allergic reaction: rash, itching, or anaphylaxis. - Cardiac arrhythmia: abnormal heart rhythm.

Before using Ipratropium/Salbutamol, consider the following safety measures.

- Assess cardiac history: patients with heart disease should be monitored. - Review electrolyte status: low potassium may increase risk of arrhythmias. - Evaluate for glaucoma: anticholinergic component can raise intra‑ocular pressure. - Monitor for paradoxical bronchospasm: discontinue if breathing worsens. - Use with caution in pregnancy: only if benefit outweighs risk. - Store below 25°C: keep in the original pack, protect from moisture.

Drug interactions can modify the safety or effectiveness of Ipratropium/Salbutamol.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Diuretics (e.g., furosemide): increase risk of hypokalemia, enhancing cardiac effects. - MAO inhibitors: can potentiate sympathomimetic effects of salbutamol.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): additive dry‑mouth and ocular pressure effects. - Theophylline: may increase risk of tachyarrhythmias. - Corticosteroids: monitor for enhanced systemic effects when combined with high‑dose inhaled therapy.